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Summary The Avon Longitudinal Study of Children and Parents (ALSPAC)
was established to understand how genetic and environmental
characteristics influence health and development in parents and
children. All pregnant women resident in a defined area in the
South West of England, with an expected date of delivery between
1st April 1991 and 31st December 1992, were eligible and 13 761
women (contributing 13 867 pregnancies) were recruited. These
women have been followed over the last 19–22 years and have
completed up to 20 questionnaires, have had detailed data
abstracted from their medical records and have information on
any cancer diagnoses and deaths through record linkage. A
follow-up assessment was completed 17–18 years postnatal at
which anthropometry, blood pressure, fat, lean and bone mass
and carotid intima media thickness were assessed, and a fasting
blood sample taken. The second follow-up clinic, which additionally
measures cognitive function, physical capability, physical activity
(with accelerometer) and wrist bone architecture, is underway
and two further assessments with similar measurements will take
place over the next 5 years. There is a detailed biobank that
includes DNA, with genome-wide data available on 410 000,
stored serum and plasma taken repeatedly since pregnancy and
other samples; a wide range of data on completed biospecimen
assays are available. Details of how to access these data are pro-
vided in this cohort profile.
Why was the cohort set up?
Detailed follow-up of study participants in ALSPAC
has focused largely on the offspring, and a previous
publication has described the methods of the study,1
with a companion cohort profile updating that previ-
ous publication and focusing on the offspring.2
However, the mothers were the participants recruited
to ALSPAC and the original investigators were clear
that the goal of the study was to determine ways in
which genotype and environmental characteristics
influence health and development in both children
and parents. Substantial information on lifestyle
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behaviours, including smoking,3,4 diet,5–7 physical ac-
tivity,8,9 alcohol10–12 and use of illegal drugs,12,13 have
been collected repeatedly since pregnancy on mothers
and their partners. Information on partners has been
collected in one of two key ways: either by responses
from the mother about their partner’s behaviour or by
responses of the partners themselves when mothers
have passed questionnaires on to their partners.
Recently, substantial funding has been obtained to
collect additional detailed data on the mothers. This
includes funding to complete genome-wide analyses,
to complete extraction of obstetric data, to invite all
mothers to a follow-up assessment—Focus on
Mothers 1 (FoM1)—and to complete a further three
follow-up assessments (FoM2–FoM4). These add-
itional funds mean that ALSPAC mothers now provide
a unique resource for understanding women’s repro-
ductive health and the impact this has on her own
future health as well as that of her children.14–16 It
also establishes ALSPAC as a truly multi-generational
cohort with extensive genetic (genome-wide data on
approximately 10 000 mother–offspring pairs) and
phenotypic data on mothers and offspring. Recent
funding to extend this resource to collect detailed
data on fathers, siblings and the next generation—chil-
dren of the children of the 1990s (COCO90s or
ALSPAC-G2)—will further enhance the study’s cap-
abilities to understand intergenerational transmission
of health and well-being.
Who is in the cohort?
All women resident in a defined geographical area in
the South West of England with an expected date of
delivery between 1 April 1991 and 31 December 1992
were eligible for inclusion. Full details of how these
women were recruited are provided in a previous pub-
lication describing ALSPAC and in the accompanying
cohort profile focusing on the index children.1,2
Figure 1 shows the numbers recruited and the flow
of these through ALSPAC, focusing on the mothers;
an equivalent flow chart focusing on the index chil-
dren is shown in the companion cohort profile.2
Describing numbers in a pregnancy cohort can be
complicated as these differ for ‘pregnancies’,
‘women/mothers’ and ‘children’. For clarity, and con-
sistency with the companion cohort profile of the
index children,2 we use the term ‘enrolled pregnan-
cies’ for recruited pregnancies and ‘women’ for
unique women in Figure 1. Within the enrolled
cohort of pregnancies, there are some women who
Questionnaires
13761 completed at 
least one questionnaire
9467 completed at 
least 10 questionnaires
2473 completed all 18 
questionnaires to date
DNA
10321 with DNA 
sample
Clinical assessment
11264 invited to Focus on 
Mothers 1 (FoM1)
4834 (43% of invited) 
attended 
Future funded assessments
3000 (select subgroup) to be 
invited to three additional 
clinic assessments (FoM2–4; 
2011–16)
Recruited pregnancy cohort 
n = 14541a Of which 674 excluded: 
69 unknown outcomes
604 no live-birth
1 live-birth only from a twin 
pregnancyIncluded pregnancy cohort
n = 13867 
Included individual womenb
n = 13761
Including 106  sib-ships







Figure 1 ALSPAC mother participant flow. aThis number of recruited pregnancies does not include 717 women who
completed one early pregnancy questionnaire and then experienced a pregnancy loss prior to 23 weeks. A description of
these pregnancies (the miscarriage substudy) is provided in the supplementary web-material available as Supplementary
Data at IJE online. bFor some subsequent data collection, additional women who were recruited 5–8 years postnatally
were included. The description of these additional recruitments is provided in the accompanying cohort profile of index
children.2 For obstetric data abstractions and for the earlier questionnaires only the 13 761 women were eligible. Later
questionnaires and invites to the Focus on Mothers clinic assessment were sent to some additional women who were
recruited 5–8 years postnatally and so the potential denominator for these is somewhat greater than 13 761 and varies for
different questionnaires










contribute two pregnancies (i.e. they had a second
pregnancy during the recruitment period) and there-
fore there are a small number of sib-ships within the
cohort. The flow diagram in this profile begins with
the enrolled pregnancies and that in the accompany-
ing profile2 goes back to ‘eligible pregnancies’, which
we have not done here in the interest of simplicity
and space. ALSPAC initially enrolled a cohort of
14 541 pregnancies. Of these 14 541 pregnancies, 674
were excluded and the remaining 13 867 pregnancies
included 13 761 unique women. As noted in the
accompanying profile focusing on the children,2 add-
itional participants were recruited and added to the
cohort after the initial recruitment period when chil-
dren were in school-years. With respect to the
mothers, these additional recruitments will not have
extracted obstetric data or questionnaire data for
questionnaires that were sent prior to their recruit-
ment. They were sent all questionnaires following
their recruitment and were invited to the Focus on
Mothers assessment (Figure 1).
The 1991 census was used to compare the popula-
tion of mothers with infants <1 year of age resident
in Avon with those in the whole of Britain, and to
further compare participants in ALSPAC (using data
collected 8 months postnatal) with mothers in
Avon. The 8-month postnatal questionnaire was com-
pleted by 80% of the enrolled cohort of pregnancies,
meaning that this comparison illustrates socio-
demographic differences resulting from both incom-
plete enrolment and lack of response to the 8-month
questionnaire. Mothers of infants in Avon were
slightly more likely than those in Britain to live in
owner-occupied accommodation and to have a car
available to the household and less likely to have
one or more persons per room and be non-White;
the proportion of women who were married was simi-
lar in Avon and Britain (Table 1). ALSPAC partici-
pants at 8 months post childbirth were more likely
than mothers in Britain, and also those in Avon, to
live in owner-occupied accommodation and have a car
in their household and less likely to be non-White.
ALSPAC mothers were more likely to be married
than either the equivalent population of Avon or
Britain. Interestingly, despite generally having higher
socio-economic position indicators on average than
equivalent women in both Avon and Britain,
ALSPAC mothers were somewhat more likely to be
living in overcrowded conditions (a higher proportion
with on average more than one person per room)
than either Avon or British women.
To date, two key ‘sub-studies of ALSPAC mothers’
have been completed in those who (i) experienced a
pregnancy loss prior to 23 weeks gestation17 and (ii)
are lesbian mothers.18–20 An additional two substudies
have recently started: (i) a qualitative study with repeat
in-depth interviews being conducted over the next 5
years to examine women’s attitudes towards ageing
and health as they go through midlife and the
peri-menopause and (ii) a photographic project used
to illustrate how women see themselves in midlife.
All four of these substudies are described in more
detail in the supplementary web-material available as
Supplementary Data at IJE online.
How often have they been
followed up?
During the index pregnancy, most women were sent
three questionnaires; some who were recruited late in
pregnancy will only have been sent one or two and a
small number completed four. Since the index preg-
nancy, over a period of some 20 years, women have
been sent 16 additional questionnaires that refer to
their own health and well-being (questionnaires that
they completed that asked about their study child are
not discussed here).
Figure 2 shows the response to the first 18 (3 ante-
natal and 15 postnatal) questionnaires to mothers
about themselves; the 16th postnatal questionnaire,
which focuses specifically on symptoms of polycystic
ovarian syndrome and incontinence, has recently been
mailed to the mothers. Response declined slightly
over pregnancy and the first 33 months postnatal,
but then remained constant at 70% until 152
months (12–13 years) postnatal, when there was a
decline, with recent responses being between 50% and
60%. A similar pattern has been seen in recent
responses from the index children,2 and this recent
decline may reflect ‘study fatigue’ or be related to
the size of the questionnaires, which have been
larger in recent years as the number of collaborators
in ALSPAC has increased. As a response to this, we
are limiting the size of subsequent questionnaires and
exploring the acceptability and response to web-based
questionnaires.
The decline in questionnaire responses over
time somewhat exaggerates participation attrition as
11 264 (82%) of mothers still remain engaged with
Table 1 Socio-demographic characteristics of mothers in










Owner occupier 63.4 68.7 79.1
1þ person/room 30.8 26.0 33.5
Car in household 75.6 83.7 90.8
Married couple 71.8 71.7 79.4
Non-White mother 7.6 4.1 2.2
Data for mothers in Great Britain and Avon from the 1991
census and based on women with an infant <1 year of age.
Data from ALSPAC based on questionnaire responses at 8
months postnatal collected between 1992 and 1993; 80% of
the enrolled pregnancy cohort from ALSPAC completed this
questionnaire.










the study and they exhibit different patterns of ques-
tionnaire response. For example, some will complete
every other questionnaire or not complete one for sev-
eral occasions and then respond. This means that we
can often include a large proportion of participants in
analyses using repeat (change) in questionnaire char-
acteristics and can also combine data from question-
naires close together to increase numbers with a
specific outcome.
In 2008, funding was secured to invite all mothers
still engaged with the study to a follow-up clinic
(FoM1). Of the 11 264 eligible women, 4834 (43%)
attended and provided valid data for the FoM1
follow-up clinic. Table 2 shows differences in baseline
characteristics between the 6430 women who were
invited but did not attend FoM1 and the 4834 who
did attend. Women who did not attend were younger,
from lower social class backgrounds and less likely to
have a university degree and were more likely to have
had two or more children prior to the index preg-
nancy, compared with those who did attend. Those
who did not attend also had higher pre-pregnancy
body mass index (BMI) and were more likely to ex-
perience hypertensive disorder of pregnancy, though
mean gestational weight gain and the occurrence of
gestational diabetes were similar in those attending
and those not.
Further funding was secured in 2011 to complete
three further clinics (FoM2–FoM4) on the subgroup
of 3000 women who were pre- or peri-menopausal at
the time of FoM1 and likely to make a transition
through one or more stages of the menopausal
Table 2 Baseline characteristics in women who attended the first follow-up clinic assessment of mothers (17–18 years
postnatal) and those who were invited but did not attend
Characteristic
Mean (SD) for continuously measured









Age at birth of child (years) 27.2 (5.0) 29.6 (4.5) <0.001
Pre-pregnancy BMI (kg/m2) 23.2 (4.1) 22.5 (3.4) <0.001
Weight gain in pregnancy (kg) 12.4 (4.9) 12.6 (4.3) 0.07
Head of household manual occupational social class (%) 23.8 11.8 <0.001
Had a university degree at time of index pregnancy (%) 9.7 18.7 <0.001
Already had 2 or more children at time of index pregnancy (%) 7.1 4.9 <0.001
Experienced HDP in index pregnancy (%) 17.1 14.8 0.001
Experienced gestational diabetes in index pregnancy (%) 0.4 0.6 0.25
*Assessing the null hypothesis that there is no difference in distributions between those who attended and those who did not
attend the follow-up clinic; unpaired t-test for continuous variables and chi-square test for categorical variables.
HDP, hypertensive disorder of pregnancy.
Figure 2 ALSPAC mother questionnaire response. The denominator is the number of women who were sent the ques-
tionnaire at each time period. This varies from 13 761 at the start of the study to 8512 for more recent questionnaires, as
women who have died or requested to be withdrawn from further questionnaires or have a study break are taken into
account. A total of 11 264 women remain in contact with the study










transition during the next 5 years. These assessments
will take place between now and 2016.
What has been measured?
The ALSPAC resource has a scale and richness that is
unprecedented in epidemiological studies and it is
beyond the scope of a single paper to list all data,
at each time point, which have been collected.
Instead, here, and in the companion children’s
cohort profile,2 we summarize the key areas of data
collection. A comprehensive guide to all measure-
ments in all participants can be found on our website
(http://www.bris.ac.uk/alspac/). Key measurements
that have been completed or are planned on the
ALSPAC mothers are summarized in Table 3 and the
biobank resource for the mothers is summarized in
Table 4.
Obstetric medical record data
The information sheets given to the women in preg-
nancy stated that data from medical records would be
abstracted, unless she specifically indicated that she did
not want this to occur. Initially, very detailed prenatal,
labour and early postnatal data were abstracted on spe-
cific subgroups; for example, all women whose child
was delivered by caesarean section or had an instru-
mental delivery, based on funded nested studies; and
data were also abstracted on a random sample of 2500
healthy controls. In total, these early abstractions were
completed on 8369 pregnancies. Recent funding has
supported abstraction on remaining records, but with
a focus on the antenatal period primarily. Thus, detailed
antenatal data and some pregnancy and postnatal data
have now been abstracted on all 13 706 pregnancies
where the medical records could be retrieved.
Additional information on other complications of preg-
nancy, results of ultrasound examinations, details of
hospital admissions, investigations and treatments up
to 14 days postpartum are available on 8369 pregnancies
(Table 3).
Trained research midwives/nurses abstracted data
from medical records. For the 5437 abstracts that
were recently completed, data were abstracted directly
onto an electronic database with inbuilt quality con-
trol. Early abstractions were onto a paper pro-forma
and were later transferred to an electronic database.
There is no between type of data abstraction, between
abstractor or variation in mean values of abstracted
data. For the 5437 records abstracted onto electronic
databases, repeated data entry checks demonstrated
error rates consistently <1%.
The detailed repeat measurements of weight, blood
pressure, proteinuria and glycosuria have been used
to derive trajectories and/or latent classes represent-
ing different patterns of change in these, and also
to derive medical conditions using different criteria,
for example the International Society for the Study
of Hypertension in Pregnancy (ISSHP) criteria for
gestational hypertension and pre-eclampsia.21 Details
of the derived obstetric data, including the statis-
tical methods used to derive them, are provided
in the supplementary web-material available as
Supplementary Data at IJE online.
Opportunistic clinic assessment
Opportunistic measures were obtained from mothers
accompanying their children to follow-up Focus visits
held when the children were 12–13,413–14 and 15–
16 years of age. These measurements were conducted
if clinic staff and time were available. Table 3 details
the complete list of measurements and numbers at
each time point.
Completed FoM1 clinic assessment
Between November 2008 and March 2011, all
ALSPAC mothers who were alive and had not with-
drawn (N¼ 11 264) were invited to a clinic assess-
ment—FoM1—and 4834 women completed the
assessment. This clinic was funded to examine the
association of pregnancy characteristics with later car-
diometabolic health in the mother, and the measure-
ments conducted reflect this focus on cardiometabolic
health (Table 3).
Planned future clinic assessments
We have secured funding to complete a further three
clinics on the mothers (FoM2–4). The focus of these
clinics (together with data collected at FoM1) is to
examine changes in hormonal, cardiometabolic func-
tion, musculoskeletal health, cognitive function and
physical capability between mid-1940s and mid-1950s
and to explore the extent to which menopausal/hormo-
nal, life circumstances (e.g. changes in occupation,
income and household/family structure), behaviour
(e.g. change in smoking and physical activity) and gen-
etic and epigenetic characteristics might explain any
changes. In view of this focus, FoM2–4 will be con-
ducted on a subgroup of the ALSPAC mothers
(N¼ 3000) who at the FoM1 clinic assessment were
aged 547 years, still menstruating regularly and who
had not had a hysterectomy or oophorectomy—these
characteristics aim to identify women who were pre-
or peri-menopausal and likely to go through at least
one stage of the menopausal transition over the period
of the assessments. FoM2 began in July 2011 and by the
middle of February 2012, 968 women had completed
this assessment, with a further 369 booked into ap-
pointments to the end of April 2012.
Record linkage
ALSPAC mothers are flagged for mortality and cancer
with the Office of National Statistics registries. To
date, several hundred cancer events have been regis-
tered among this cohort, with 454 registrations of cer-
vical cancer, 288 of breast cancer, 107 of any type of










Table 3 ALSPAC mother’s summary of measurements
Self-reported questionnaire measures
From pregnancy to 20 years postnatal; numbers with data vary from 5000 to 13 700; more than 9467 have completed at
least 10 of the 18 questionnaires to date.a
 Demographics: Age, marital status, socio-economic position, household composition, ethnicity, parity
 Personality: Questionnaire assessment of personality, attitudes, behaviours, feelings about becoming pregnant and about
becoming a mother
 Life course characteristics: Retrospective report of their early life exposures and characteristics, including birthweight,
parental occupations, childhood housing conditions
 Health-related behaviours: Smoking, alcohol, diet, physical activity, illegal drug use
 Health:
 Mental health (repeatedly assessed depression and anxiety by using validated scales);
 Reproductive health [repeatedly assessed pregnancies (including their outcomes and pregnancy complications),
contraception, hormone replacement, menstrual patterns, cessation of menstruation, hysterectomy/oophorectomy and
in 2011 validated questions for identification of those with polycystic ovary syndrome, stress and urge incontinence]
 Cardiometabolic health (repeatedly assessed family history, own history of diagnosis of hypertension, diabetes, high
cholesterol, since 2010 Rose angina and peripheral vascular disease questionnaires and questions about diagnoses of
angina and myocardial infarction and of experience of angioplasty or coronary artery by-pass)
 Musculoskeletal health [repeatedly assessed diagnosis of arthritis (including type and joints affected), since 2008
asked about doctor diagnosis of osteoporosis, falls and fractures]
 Respiratory health (repeatedly asked about diagnoses and symptoms of asthma and bronchitis)
 Medication use (repeatedly asked to report about names, dosage, frequency and reason of prescribed and
over-the-counter medication)
 Childhood health (retrospective report of hospital admissions, diagnoses, injuries and illnesses in childhood)
 Family health [retrospective report of whether parents remain alive, age and cause of death if they had died, family
history of specific conditions (e.g. cardiovascular disease, diabetes, cancer)]
Obstetric data abstracted from medical records
Available on 13 706 womena
 Repeat measurements of weight [median (IQR) measurements per woman: 12 (9–13)], blood pressure [median (IQR):
13 (11–16)], protein- and glycos-uria [median (IQR): 12 (9–14)], peripheral oedema [median (IQR): 13 (11–16)],
haemoglobin [median (IQR): 3 (2–3)].
 Derived (from repeat blood pressure and proteinuria measurements and questionnaire data) hypertensive disorders of
pregnancy (pre-existing hypertension, gestational hypertension, pre-eclampsia, pre-clampsia superimposed on
pre-existing hypertension)
 Medical record recorded diagnoses of gestational diabetes, anaemia and other complications of pregnancy
 Results of booking clinic blood tests—blood group, haemoglobin, rubella immunity
 Whether amniocentesis or chorionic villus sampling was undertaken
 Hospital admissions (whether or not any occurred on the total sample; details of dates, length of stay and reason
available on 8369)
 Results of ultrasound examinations (on 8369)
 Method and place of delivery
 Placental weight (available on 5769)
 Postnatal health (presence of anaemia on the total sample; details of other conditions and treatments up to 14 days
postnatal (or when were discharged from care) available on 8369)
Opportunistic clinic assessments
Completed on mothers when they attended Focus assessments with their index child and when staff and resources allowed
these assessments; numbers and time points vary and are detailed by each measure
 Anthropometry: At 12–13 years postnatal: weight (N¼ 439), standing height (N¼ 439). At 15–16 years postnatal: weight
(N¼ 2412), standing height (N¼ 2412), seated height (N¼ 1635), waist (N¼ 1638), hip (N¼ 1637), arm (N¼ 1641) and
head (N¼ 1641) circumference
 Bioimpedance for percent body fat: At 12–13 years postnatal (N¼ 439). At 15–16 years postnatal (N¼ 2405)
 Dual-energy X-ray Absorptiomtry (DXA) whole body and hip scan for fat, lean and bone mass: At 15–16 years postnatal
(N¼ 2086)
 Systolic and diastolic blood pressure and pulse rate: At assessment 12–13 years postnatal (N¼ 389). At 13–14 years
postnatal (N¼ 4173). At 15–16 postnatal (N¼ 3924)
 Emotional well-being and responses: Locus of Control at 12–13 years postnatal (N¼ 4069) and at 15–16 years postnatal
(N¼ 4490). Development And Well-Being Assessment (DAWBA) at 15–16 years postnatal (N¼ 4242)
(continued)










skin cancer, 15 of colorectal cancer and 10 of lung
cancer, to October 2011.
Biological samples and measurements
Table 4 summarizes the biobank samples that have
been collected on ALSPAC mothers; this table also
provides information on the availability of these re-
sources to potential collaborators.
Repeated blood samples on each woman collected as
part of routine antenatal care were retrieved and
these, together with further collections during the
follow-up clinics of the children and mothers, have
been used to establish a maternal DNA bank and
immortalized lymphoblastoid cell lines. DNA was
extracted using any of a phenol–chloroform, salting-
out or guanidine hydrocholoride extraction methods,
and concentration has been determined using
PicoGreen assessment; 95% of the samples have at
least 20 ml of DNA at a concentration of 50 ng/ml. A
recently awarded Wellcome Trust grant provides
funds for genome-wide assays (Illumina 660 W-quad
BeadChip) on all 10 321 women who provided con-
sent for genetic testing and on whom high-quality
Table 3 Continued
 Cognitive function: Theory Of Mind (TOM) assessment at 13–14 years postnatal (N¼ 4913). Wechsler Abbreviated Scale
of Intelligence (WASI) at 15–16 years postnatal (N¼ 3900)
 Visual acuity and retinal photography at 15–16 years postnatal (N¼ 1005)
FoM1 follow-up clinic assessment
Completed 2009–11, N¼ 4834a
 Anthropometry: weight, height, waist, hip and head circumference
 DXA whole body and hip scan for fat, lean and bone mass
 Seated and standing systolic and diastolic blood pressure and pulse rate
 Carotid intima-media thickness and arterial stiffness
 Brief computer-completed questionnaire collecting information on menstrual cycle (including date of last menstrual
period), contraception, use of hormone replacement, hysterectomy/oophorectomy, current use of any medications
(including dosage, frequency and reason), allergies
 Fasting blood samples for storage and assays of haemoglobin, glucose, insulin, pro-insulin, lipids, C-reactive protein, sex
hormones and for DNA in any women on whom a previous sample was not available
Funded and ongoing future FoM2–4 clinics
These data will be collected on 3000 women who were pre- or peri-menopausal at the time of FoM1 and likely to change
through one or more of the stages of the menopausal transition over the next 5 years; FoM2 began in August 2011 and to
date (February 2012) approximately 700 women have attended and completed the assessments
 Anthropometry: weight, height, waist, hip and head circumference
 DXA whole body and hip scan for fat, lean and bone mass
 Peripheral quantitative computer tomography of radius to assess bone structure
 Seated and standing systolic and diastolic blood pressure and pulse rate
 Cognitive function: logical memory test, backwards digital span, spot the word test, digital symbol coding
 Physical capability: hand-grip strength, chair rise, balance and 3-m walk test
 Physical activity: accelerometer assessed
 Brief computer-completed questionnaire collecting information on menstrual cycle (including date of last menstrual
period), contraception, use of hormone replacement, hysterectomy/oophorectomy, current use of any medications
(including dosage, frequency and reason), allergies
 Fasting blood samples for storage and assays of haemoglobin, glucose, insulin, pro-insulin, lipids, C-reactive protein, sex
hormones and for DNA in any women on whom a previous sample was not available
Record linkage
All recruited women who provided permission have been linked to the National Health Service (NHS) Central Register,
which provides data on the following.
 Death (including underlying and contributing causes and date)
 Cancer (including type, site and date of registration (approximate date of diagnosis)
 Emigration (out of the UK)
aNumbers given for a particular questionnaire or focus follow-up visit assessment refer to the number who completed at least some
of the questions/measurements. For individual measurements, the N will vary but only by small amounts. Where it is markedly
different (e.g. for placental weights in the obstetric data abstraction), this is noted.
Environmental toxin data have also been collected from households and samples in ALSPAC; these are detailed in the companion
cohort profile focusing on the offspring.2










genomic DNA at sufficient concentration and volume
(minimum 20 ml of DNA at a concentration of 50 ng/
ml) is available. A large number of candidate genetic
variants have been typed on the mothers. Recently,
completion of the genome-wide assays means that
there are now approximately 10 000 mother–offspring
pairs in ALSPAC with genome-wide data; this reduces
to approximately 8000 when within each group of
mothers and offspring all relatives (to level of
cousin) are removed.
DNA methylation has been assessed on subgroups of
the mothers; for example, on their pregnancy DNA
samples in those with different levels of pre-
pregnancy BMI or of weight gain. Recent funding
will allow global DNA methylation using the
Illumina Human Methylation 450 K DNA Bead Chip
to be completed on all women with relevant samples
during pregnancy and then on samples collected at
each of FoM1–FoM4.
Routine blood test results from the obstetric records,
including rubella immunity status, blood group
and haemoglobin levels are available. To date, total
cholesterol, vitamin D [25(OH)D2 and D3], calcium,
phosphate, fatty acid profile, trace metals and albu-
min have been assessed on the stored pregnancy sam-
ples. In addition, funding is available, and assays have
begun to complete measurements of thyroid function
and thyroid antibodies during pregnancy. A number
Table 4 Biological samples on ALSPAC mothersa







Pregnancy (1990 to early 1993) Serum 1 ml 3 6120
Serum (AFP residue) 500 ml 3 3449
Serum (rubella residue) 500 ml 1 2598
Plasma (hep) 1 ml 6 6167
Plasma (hep) 500 ml 5 467
Whole blood (EDTA) 2 ml 1 7501
Red cells (EDTA) 1 1507
Blood spot (heparin) 10 spots 5731
Red cells (heparin) 1 1651
White cells (heparin) 1 2316
Urine 1 ml 4 8575
Urine 5 ml 5 7723
Delivery (1991 to early 1993) Placenta (formalin) 1 (whole placenta) 8933
Early postnatal (1993) Hair 1 4928
Toe nails 1 4959
11–15 years postnatal (2004–08) Plasma (hep) 500 ml 4 5211
Plasma (hep) 200 ml 9 5221
16–18 years postnatal (2009–11) Plasma (hep) 500 ml 4 4467
Plasma (hep)200 ml 9 4424
Plasma (EDTA) 500 ml 3 4449
Plasma (EDTA) 200ml 5 4381
Plasma (fluoride) 300 ml 5 4298
White cells (EDTA) 1 3967
Continuous since recruitment until now DNA NA 10 321
Cell lines NA 5140
NA, not applicable.
aData compiled and accurate on 29 February 2012.
bKey to sample additives: Hep: heparin, EDTA: ethylenediamineteraacetic acid.
cThe last aliquot of most samples is not available for collaborative research studies unless special permission is gained from the
executive (i.e. at the moment we keep at least one aliquot of any sample for a potential major research project rather than allow
exhaustion) and since compiling this table some aliquots may have been reserved for analyses and therefore fewer may be
available.










of nested case–control studies have also had more
expensive assays completed on case–control sub-
groups, generally of a few hundred participants
each. For example, IGF1, IGF2, IGF-binding protein
3, sex hormone binding globulin and testosterone
were assayed in 151 cases of cervical cancer, 69
cases of breast cancer and 443 healthy controls.22
Assays of fasting glucose, insulin, pro-insulin, total
and high-density lipoprotein cholesterol (low-density
lipoprotein cholesterol will be estimated from these),
triglyceride levels and C-reactive protein and sex hor-
mones have been (or are being) completed on the
FoM1 samples, with similar measurements funded
for the samples that will be collected at FoM2–4
(Table 3).
In addition to blood samples, random urine samples
were collected during pregnancy, the placentas from
the index pregnancy have been retained and stored
and hair and toenail samples were collected in 1993
when the offspring were infants. Two studies analys-
ing anatomical and some histopathological features of
the placentas are currently funded. The first is to de-
termine if the size and shape of the placental surface
predicts hypertension in children. The second is a
case–control study examining vascular branching
structures and histopathological characteristics to in-
vestigate the intrauterine origins of autism risk. Once
these studies are completed, the placental data will be
incorporated into the database and available for col-
laborators to use. To date, creatinine has been mea-
sured on the pregnancy urine samples and iodine and
cotinine are currently being assayed.
What has it found? Key findings
and publications
Since data collected in ALSPAC spans at least two gen-
erations, the study has facilitated analyses that have
made major contribution to a considerable number of
areas, with full details on the study website (http://
www.bris.ac.uk/alspac/). Examples of some of the sci-
entific areas that data from the ALSPAC mothers study
have contributed to are summarized below.
Understanding of relationships between
maternal characteristics and offspring
outcomes
There are several hundred publications that have
examined a wide range of maternal exposures with
later offspring outcomes. By way of examples, we
have shown that greater maternal gestational weight
gain is associated with a more adverse cardiometa-
bolic risk profile in offspring,23 that hypertensive dis-
orders of pregnancy are associated with offspring
blood pressure,15 but not other cardiovascular out-
comes,16 and that maternal glycaemia in pregnancy
is associated with offspring obesity and fasting insulin
and glucose.24,25 Using ALSPAC data, associations of
prenatal anxiety with offspring diurnal salivary cor-
tisol patterns,26 childhood behaviour27–29 as well as
childhood asthma30 have been demonstrated. Greater
maternal prenatal fish consumption has been shown
to be positively associated with verbal IQ and other
outcomes in the offspring.31 Data from ALSPAC and
others studies show that maternal insulin glucose
kinase genotype is associated with offspring birth
weight.32 Of relevance to parenting programmes
aimed at improving child development and maternal
outcomes, we have shown that targeting at-risk
groups based on young maternal age, as current UK
policy recommends, will miss the majority of those
with adverse outcomes, whereas using other maternal
characteristics (education, financial difficulties, part-
ner status, smoking in pregnancy and antenatal de-
pression) would markedly increase the proportion of
those at risk who are correctly identified.33,34
Identifying causal developmental risk factors
The availability of questionnaire data on the mother’s
partners (sometimes reported by the mother and
sometimes by the partner) as well as mothers, has
been used to assess whether there is a direct biolo-
gical effect of intrauterine exposures on offspring
health status.35,36 For example, comparing associ-
ations of prenatal maternal and paternal smoking
suggest that foetal exposure to maternal smoking in
utero predisposes offspring to shorter birth length and
lower weight and ponderal index at birth, as well as
faster increases in length and adiposity in infancy,37,38
but does not appear to be causally related to adiposity
in later childhood.38 Similar parental comparisons
suggest that exposure to maternal smoking in utero
is not causally related to childhood IQ, blood pressure
or bone density.4,11,39 We have also compared mater-
nal and paternal pre-pregnancy BMI, assessed by
questionnaire at the time of recruitment, in their as-
sociations with offspring BMI4 and bone density,40
with the similarity of maternal- and
paternal-offspring associations suggesting that mater-
nal pre-pregnancy greater BMI does not cause, via
intrauterine mechanisms, greater BMI or lower bone
density in offspring in later life. In contrast, maternal
pre-pregnancy BMI was found to be more strongly
associated with offspring dual-energy X-ray absorp-
tiomtry determined fat mass at mean age 10 years
compared with paternal pre-pregnancy BMI, though
the difference between the two was small.41
The strong collaborative links between ALSPAC and
a large number of other birth cohorts across the world
have also facilitated cross-cohort comparisons that
contribute to understanding causality. For example,
the confounding structures related to whether
mothers breastfeed or not are markedly different be-
tween populations in high income countries such as
the ALSPAC mothers (breastfeeding more likely in
those from higher socio-economic backgrounds)
than in those from low- or middle-income countries










(breastfeeding not related to socio-economic position
or more likely in those from lower socio-economic
backgrounds). We have used this difference to dem-
onstrate that breastfeeding is likely causally related to
greater IQ in offspring in later life, but is not causally
related to their later BMI or blood pressure.42
Women’s reproductive health and its
relationship to other health outcomes
A key programme of work that has utilized data col-
lected around the time of recruitment has been
associated with pre- and postnatal depression. This
has characterized different features of these conditions
and identified risk factors for depression both during
and following pregnancy.43–47 A key finding in this pro-
gramme of work was that depressive symptoms had a
higher prevalence during pregnancy than postnatally.48
Using the repeat measurements of blood pressure in
pregnancy, we have demonstrated different trajec-
tories of blood pressure change between women
who are normotensive, have existing hypertension or
experience gestational hypertension or pre-eclampsia,
which raise the possibility of being able to identify
women earlier in pregnancy who may be destined
for pre-eclampsia.49 We have also shown that estab-
lished risk factors for pre-eclampsia and gestational
hypertension are also associated with baseline blood
pressure and change in blood pressure and protein-
uria during pregnancy suggesting a continuum of risk
that extends to women who do not meet conventional
diagnostic thresholds.50,51 With data from the largest
sample size and with most repeat measurements to
date, we have found that in normal pregnancy the
physiological increase in blood pressure starts at 18
weeks of gestation (95% CI 17–19 weeks), rather
than the 20-week point, which is used in definitions
of hypertensive disorder of pregnancy.50
We have found that hypertensive disorders of preg-
nancy and gestational diabetes are associated with
different cardiovascular risk factors in women 18
years post-pregnancy.14 Using the opportunistic
clinic measurements as outcomes, we have shown
that greater gestational weight gain is associated
with greater adiposity and higher blood pressure in
the mothers 15–16 years post-pregnancy.52 We have
attempted to understand more about different pat-
terns of gestational weight gain and what might ex-
plain these differences, and have observed that
genetic variants associated with greater adiposity in
general in European populations are not associated
with gestational weight gain,53 but age, education,
parity and smoking are associated with different pat-
terns of weight gain in pregnancy.54
Genetic influences on health and using
genetic variants to understand causal effects
of modifiable risk factors
Even prior to the recent collection of genome-wide data
in ALSPAC mothers, it contributed (as a replication
sample) to several genome-wide association studies
that have identified variants that are robustly asso-
ciated with body composition.55–57 With the recently
completed genome-wide data on ALSPAC mothers, we
are currently leading, and contributing to, a large
number of genome-wide association studies concerned
with maternal genetic contributions to their pregnancy
characteristics and to perinatal outcomes. The ALSPAC
mothers have also contributed to important candidate
gene associations. For example, variants in the Factor V
Leiden gene were found to be associated with
pre-eclampsia but not with intrauterine growth restric-
tion.58 In other candidate gene approaches, we have
shown that in women who smoke at the start of preg-
nancy a common genetic variant in the 15q24 nicotinic
acetylcholine receptor gene cluster (CHRNA5–
CHRNA3–CHRNB4) is associated with being less
likely to quit smoking during pregnancy,59 whereas a
variant in the catechol O-methyltransferase (COMT)
gene, that is believed to affect brain dopamine levels,
is weakly related to how heavily women smoke, but not
to other characteristics of smoking in pregnancy.60 A
non-synonymous variant in the alcohol dehydrogenase
1B was found to be strongly associated with
self-reported prenatal alcohol use in the ALSPAC
mothers,10 and genetic variants in the fatty acid desa-
turase gene cluster predict the amount of red blood cell
docosahexaenoic and other polyunsaturated fatty acids
in pregnant women.61 We have also shown that the
Val66Met polymorphism in the brain-derived neuro-
trophic factor is associated with BMI,62 but does not
appear to be clearly associated with depression.63 The
mothers have also contributed to a number of studies
where genetic variants are used as instrumental vari-
ables to examine the causal effect of non-genetic modi-
fiable risk factors (Mendelian randomization
studies).64,65 For example, they have contributed to stu-
dies using this approach, which suggest that folate
intake by women is not related to their BMI66 or that
of their offspring in later life.67
What are the main strengths and
weaknesses?
The main strengths of the ALSPAC mothers’ cohort
are: its sample size; the duration of follow-up and
availability of repeat measures; genome-wide data
and extensive phenotypic data; and funds to collect
repeat measurements of DNA methylation. The ability
to link these data to those of other family members—
currently, the index children with very detailed gen-
etic and phenotypic data,2 but with funds to also
collect genetic and phenotypic data on the partners
of these women and on their grandchildren—is also
a major strength.
Limitations include the majority of participants of
White ethnicity, which limits the generalizability
of findings to other ethnic groups and ethnic










comparisons, though has some advantages where a
homogeneous ethnic group is required (e.g. in some
genetic association studies). Whereas it is logical and
convenient to recruit women into a birth cohort study
when they are already pregnant, it is not necessarily
the best eligibility criterion for questions related to
women’s health in general. This is because the
index pregnancy is a somewhat arbitrary baseline in
the context of the participating women’s life course.
An additional, and no less important, reason is that
although a majority of women do experience preg-
nancy and have children, some do not and this
group is not represented in a cohort of women re-
cruited in pregnancy. That said, current Office of
National Statistics data show that for UK women in
the age range of the ALSPAC mothers, 85–88% will
have at least one child (http://www.statistics.gov.
uk/statbase/Product.asp?vlnk¼5768). Therefore, our
findings would be relevant to the large majority of
UK women and for many associations to women
from high-income countries in general. A related limi-
tation is that women who had been recruited to
ALSPAC but then experienced an early pregnancy loss
(before 23 weeks) were not followed up (see supple-
mentary web-material available as Supplementary Data
at IJE online for details of the miscarriage substudy).
A further limitation is that it is only recently that a
detailed follow-up examination of the mothers has
been funded. This means that understanding the ef-
fects of early postnatal exposures (that require clinical
assessment) on later maternal health or of changes in
exposures (e.g. changes in measured body compos-
ition, blood pressure or blood glucose levels) through
pregnancy and the early postnatal period cannot be
assessed with this resource. This ‘delay’ between ini-
tial recruitment and a dedicated clinic follow-up of
the mothers may also have influenced the response
to the FoM1. It has at times been difficult for clinic
staff, as mothers increasingly questioned why they
were not allowed some assessments (notably dual-
energy X-ray absorptiometry scans of bone density)
that were performed on their index children whom
they diligently brought repeatedly to assessments.
As with all prospective cohort studies, the number
of women being followed up declines over time.
Attrition in ALSPAC has been greater for those who
experienced greater adversity during the index preg-
nancy (including factors such as early pregnancy
complications, inadequate housing and lack of social
support),68 and women who attended the recent
FoM1 clinic assessment were older, less socio-
economically deprived and more healthy at recruit-
ment than those who were invited but did not
attend. We have recently explored likely selection
bias from attrition in ALSPAC and this suggests
that, with respect to health inequalities, attrition re-
sults in underestimation of perinatal effects and later
offspring education effects, but may not have a
marked impact on maternal behaviours such as
smoking.68 We have also used multiple imputation
to examine bias related to attrition and to appropri-
ately correct for this in several publications, although
this can be a complex procedure, depending on the
analysis model under consideration.69
Can I get hold of the data? Where
can I find out more?
The ALSPAC executive is very keen to support collab-
oration and easy access to all aspects of the data by
any researchers. Details of how to access the data can
be found on the study website (http://www.bristol.ac.
uk/alspac/), in the supplementary web-material avail-
able as Supplementary Data at IJE online accompany-
ing this cohort profile, and in the companion cohort
profile focusing on the index children.2
Supplementary Data
Supplementary Data are available at IJE online.
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 The ALSPAC mothers cohort has contributed to understanding the associations of maternal
pregnancy-related changes with the mother’s and her offspring’s future health.
 Through the use of genetic variants as instrumental variables, comparisons of maternal and paternal
exposures with offspring outcomes, and cross-cohort comparisons with studies from low- and mid-
dle-income countries, ALSPAC has provided evidence on whether different intrauterine exposures are
causally associated with later offspring outcomes.
 It has contributed to understanding genetic determinants of a number of health-related phenotypes.
 It has contributed to understanding the relationship of women’s reproductive health to healthy
ageing and well-being.
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